Advances in COVID-19 mRNA vaccine development
E Fang, X Liu, M Li, Z Zhang, L Song, B Zhu… - Signal transduction and …, 2022 - nature.com
To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
Breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) in fully vaccinated individuals are receiving intense scrutiny because of their importance …
2) in fully vaccinated individuals are receiving intense scrutiny because of their importance …
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Abstract The SARS-CoV-2 Omicron variant was first identified in November 2021 in
Botswana and South Africa,–. It has since spread to many countries and is expected to …
Botswana and South Africa,–. It has since spread to many countries and is expected to …
Effectiveness of BNT162b2 vaccine against omicron variant in South Africa
S Collie, J Champion, H Moultrie… - New England Journal …, 2022 - Mass Medical Soc
Preliminary Data on Vaccine Protection against Omicron Using a test-negative study design
focused on the period of dominance of the B. 1.1. 529 (omicron) variant in South Africa …
focused on the period of dominance of the B. 1.1. 529 (omicron) variant in South Africa …
[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection …
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection …
Homologous and heterologous Covid-19 booster vaccinations
RL Atmar, KE Lyke, ME Deming… - … England Journal of …, 2022 - Mass Medical Soc
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective …
have received emergency use authorization in the United States are highly effective …
[HTML][HTML] Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and …
JM Ferdinands - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
Vaccine effectiveness (VE) against COVID-19–associated emergency department/urgent
care (ED/UC) visits and hospitalizations was higher after the third dose than after the second …
care (ED/UC) visits and hospitalizations was higher after the third dose than after the second …
Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar
Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and
the emergence of the omicron (or B. 1.1. 529) variant of the severe acute respiratory …
the emergence of the omicron (or B. 1.1. 529) variant of the severe acute respiratory …
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England
Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in
England starting on 14 September 2021. We used a test-negative case–control design to …
England starting on 14 September 2021. We used a test-negative case–control design to …
[HTML][HTML] Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations …
MG Thompson - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
VE was significantly higher among patients who received their second mRNA COVID-19
vaccine dose< 180 days before medical encounters compared with those vaccinated≥ 180 …
vaccine dose< 180 days before medical encounters compared with those vaccinated≥ 180 …